Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US6211342A · kind A · utility
49Cited by
6References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 18, 1996 |
| Grant date | Apr 3, 2001 |
| Priority date | — |
| Expiry date | Jul 18, 2016 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/807
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention describes a soluble fusion protein composed of a plurality of major histocompatibility complex (MHC) molecules linked together by a stabilizing structure herein referred to as the "linker," the MHC molecules being loaded with a specific peptide or peptides. Such fusion proteins can be used as a method for stimulating or inhibiting specific T cell clones expressing T cell receptors (TCR) restricted to the specific MHC-peptide combination. Such fusion proteins can thus be used as delivery systems to stimulate T cell immunity and as a treatment for diseases such as transplant rejection or autoimmunity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.